ImmuneOncia, WuXi Biologics partner for bispecific antibody development
ImmuneOncia will use WuXi Biologics’ services in bioassay development, cell line development, cell culture development.
Hasini Devarasetti
Latest articles
All Articles
Oravax Medical to test triple antigen oral vaccine against Omicron
The vaccine candidate is expected to be used as an independent vaccine or as a booster drug for people…
Italy approves Pfizer and BioNTech’s Covid-19 vaccine for children
The dosage for children is indicated to be a third of the authorised 30µg dose given to adults and…
RedHill Biopharma reports rise in Q3 2021 net revenues
Talicia reported a 15% increase in new prescriptions and a 117% rise compared to the third quarter of last…
UAE approves Sputnik Light vaccine as universal booster dose for Covid-19
The Sputnik Light vaccine can be administered six months after the second dose of all other vaccines used in…
First Wave BioPharma to continue Covid-19 GI infection therapy trial
The DMC recommendation was based on the review of positive safety data from the first 25 patients dosed in…
bit.bio raises $103m through series B round to develop cell therapies
bit.bio will use the funds to speed up the clinical development of opti-ox, a cell coding technology.
Boehringer Ingelheim and Thoeris to work on urea cycle disorder therapies
Boehringer Ingelheim will contribute its research and drugs development expertise for advancing medications into the clinic.
ANVISA approves PTC Translarna indication expansion to ambulatory children
Translarna was earlier approved for use by patients aged five years and above with nonsense mutation Duchenne muscular dystrophy.